Maximizing Outcomes in Relapsed/Refractory Multiple Myeloma: Tailoring Bispecific Antibody Approaches : Episode 2
MonumenTAL: Key Efficacy Outcomes
Dr Nadeem to summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma, including key efficacy outcomes from the monumenTAL trials.
EP: 1.John’s Journey with R/R MM
Now Viewing
EP: 2.MonumenTAL: Key Efficacy Outcomes
EP: 3.Implications of Talquetamab on the Current Treatment Landscape for R/R MM
EP: 4.Bispecifics in R/R MM: Selecting the Best Bispecific and Optimal Sequencing Strategies
EP: 5.Eva’s Treatment Journey With R/R MM
EP: 6.MagnestisMM: Key Efficacy Data and its Clinical Implications
EP: 7.Elranatamab: Real-World Experience and Sequencing
EP: 8.Future of R/R MM: Emerging Agents
Video content above is prompted by the following:
- What characteristics make this patient particularly suitable for treatment with a bispecific antibody?
- Can you summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma (R/R MM)?
- Could you highlight the primary efficacy outcomes from the monumenTAL trials?
Recent Videos
Related Content
